In recent years, BRAF/MEK inhibitor combinations including dabrafenib/trametinib, vemurafenib/cometinib, and encorafenib/binimetinib have been approved by the FDA, leading to median progression-free survival (PFS) of up to 14.9 months in BRAF mutant melanoma patients [4]. This evidence concerns the gene MAP2K7 and melanoma.